MedTrace Logo

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

NCT04706936 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2023-02-06

No results posted yet for this study

Summary

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on the fourth-generation of CAR-T techonology.

Conditions

Interventions

BIOLOGICAL

anti-BCMA CAR-T

Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.

DRUG

Cyclophosphamid

300mg/m2/d

DRUG

Fludarabine

30mg/m2/d

Sponsors & Collaborators

  • Carbiogene Therapeutics Co. Ltd.

    collaborator INDUSTRY

  • Second Affiliated Hospital, School of Medicine, Zhejiang University

    lead OTHER

Principal Investigators

  • Wenbin Qian · 2nd Affiliated Hospital, School of Medicine, Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2023-10-31
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04706936 on ClinicalTrials.gov